➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Boehringer Ingelheim
AstraZeneca
Mallinckrodt
Merck
Dow

Last Updated: October 19, 2020

DrugPatentWatch Database Preview

Details for Patent: 10,011,637

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 10,011,637 protect, and when does it expire?

Patent 10,011,637 protects TRULANCE and is included in one NDA.

This patent has thirteen patent family members in ten countries.

Summary for Patent: 10,011,637
Title:Ultra-pure agonists of guanylate cyclase C, method of making and using same
Abstract: The invention provides processes of purifying a peptide including a GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-251 described herein. The processes include a solvent exchange step before a freeze-drying (lyophilization) step.
Inventor(s): Shailubhai; Kunwar (Audubon, PA), Comiskey; Stephen (Doylestown, PA), Feng; Rong (Langhorne, PA), Bai; Juncai (North Augusta, SC), Zhang; Ruoping (North Augusta, PA), Jia; Jun (Shanghai, CN), Zhou; Junfeng (Shanghai, CN), Zhao; Qiao (Shanghai, CN), Zhang; Guoqing (Shanghai, CN)
Assignee: SYNERGY PHARMACEUTICALS, INC. (New York, NY)
Application Number:14/896,019
Patent Claim Types:
see list of patent claims
Compound; Process;

Drugs Protected by US Patent 10,011,637

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Salix TRULANCE plecanatide TABLET;ORAL 208745-001 Jan 19, 2017 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,011,637

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2014274812   Start Trial
Australia 2018226473   Start Trial
Australia 2020205349   Start Trial
Canada 2913737   Start Trial
China 105764916   Start Trial
Eurasian Patent Organization 201592263   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Medtronic
Merck
Dow
Johnson and Johnson
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.